Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 13, 2026

To Whom It May Concern

Company name	K Pharma, Inc.
Representative	Komei Fukushima, President & CEO
	(Securities code: 4896, TSE Growth Market)
Contact	Masato Matsumoto, Managing Director & CFO
	(TEL: +81-3-6629-3380)

Notice Regarding Revision of Earnings Forecast for the Fiscal Year Ending December 31, 2026

K Pharma, Inc. (the "Company") hereby announces that its Board of Directors, at a meeting held on November 13, 2026, resolved to revise the full-year earnings forecast for the fiscal year ending December 31, 2026, which was announced on February 12, 2026, as described below.

1. Revision of the earnings forecast for the fiscal year ending December 31, 2026 (January 1, 2026 to December 31, 2026)

	Net sales	Operating profit	Ordinary profit	Profit	Basic earnings per share
Previous forecast (A) (Announced on February 12, 2026)	Millions of yen -	Millions of yen (1,520)	Millions of yen (1,550)	Millions of yen (1,616)	Yen (139.28)
Revised forecast (B)	-	(1,093)	(1,127)	(1,192)	(102.57)
Change (B–A)	-	426	423	424	
Change (%)	-	-	-	-	
(Reference) Actual results for the fiscal year ended December 31, 2025	-	(916)	(920)	(993)	(85.59)

2. Reason for the revision

Amid continued uncertainty stemming from natural disasters across Japan, supply constraints on materials due to the situation in the Middle East, and persistently high energy prices, the Company has focused on containing expenses. As a result, the Company recorded an operating loss of ¥765 million, an ordinary loss of ¥783 million and a loss of ¥847 million for the nine months ended September 30, 2026, as stated in the "Non-consolidated Financial Results for the Nine Months Ended September 30, 2026 (Under Japanese GAAP)" announced today. As the Company will continue to contain expenses in the fourth quarter (October 1 to December 31, 2026), it has revised its full-year forecast for the fiscal year ending December 31, 2026 to an operating loss of ¥1,093 million, an ordinary loss of ¥1,127 million and a loss of ¥1,192 million. The above forecast is based on information currently available to the Company, and actual results may differ from the forecast due to various factors.